Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma

FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research communications 2024-12, Vol.4 (12), p.3165
Main Authors: Zhang, Yichi, Ojalill, Marjaana, Boyer, Antonia, Chen, Xiao Lei, Tahon, Elise, Thivolle Lioux, Gaëtan, Xia, Marvin, Abbas, Maryam, Soylu, Halime Meryem, Flieder, Douglas B, Connolly, Denise C, Molinolo, Alfredo A, McHale, Michael T, Stupack, Dwayne G, Schlaepfer, David D
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cell Line, Tumor
Cell Nucleus - drug effects
Cell Nucleus - metabolism
Cell Survival - drug effects
Cisplatin - pharmacology
Female
Focal Adhesion Kinase 1 - metabolism
Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors
Focal Adhesion Protein-Tyrosine Kinases - metabolism
Humans
MAP Kinase Signaling System - drug effects
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 12
container_start_page 3165
container_title Cancer research communications
container_volume 4
creator Zhang, Yichi
Ojalill, Marjaana
Boyer, Antonia
Chen, Xiao Lei
Tahon, Elise
Thivolle Lioux, Gaëtan
Xia, Marvin
Abbas, Maryam
Soylu, Halime Meryem
Flieder, Douglas B
Connolly, Denise C
Molinolo, Alfredo A
McHale, Michael T
Stupack, Dwayne G
Schlaepfer, David D
description FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.
doi_str_mv 10.1158/2767-9764.CRC-24-0382
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3132611851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3132611851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1025-40eccef6aaca702b3a658fd5efba9855a97a66fbf4519df17988e88d52c47483</originalsourceid><addsrcrecordid>eNpNkF1LwzAUhoMobsz9BCWX3nQmadKkl6M4FYcT3X04TRONdO1MWsF_b8t0eHVeDu8HPAhdUrKgVKgbJjOZ5DLji-KlSBhPSKrYCZoe_6f_9ATNY_wghDApucjSczRJc6EEUWKKtk-9qS0EvGoN1HhZvdvo2wY_-gaixc-h7azpIoY38E3scOHjvobON_i1CzZGPKjNFwQPDS4gGN-0O7hAZw7qaOe_d4a2q9ttcZ-sN3cPxXKdGEqYSDixxliXARiQhJUpZEK5SlhXQq6EgFxClrnScUHzylGZK2WVqgQzXHKVztD1oXYf2s_exk7vfDS2rqGxbR91SlOWUaoEHaziYDWhjTFYp_fB7yB8a0r0iFSPuPSISw9INeN6RDrkrn4n-nJnq2PqD2D6Aw3PckY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132611851</pqid></control><display><type>article</type><title>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</title><source>PubMed Central(OpenAccess)</source><creator>Zhang, Yichi ; Ojalill, Marjaana ; Boyer, Antonia ; Chen, Xiao Lei ; Tahon, Elise ; Thivolle Lioux, Gaëtan ; Xia, Marvin ; Abbas, Maryam ; Soylu, Halime Meryem ; Flieder, Douglas B ; Connolly, Denise C ; Molinolo, Alfredo A ; McHale, Michael T ; Stupack, Dwayne G ; Schlaepfer, David D</creator><creatorcontrib>Zhang, Yichi ; Ojalill, Marjaana ; Boyer, Antonia ; Chen, Xiao Lei ; Tahon, Elise ; Thivolle Lioux, Gaëtan ; Xia, Marvin ; Abbas, Maryam ; Soylu, Halime Meryem ; Flieder, Douglas B ; Connolly, Denise C ; Molinolo, Alfredo A ; McHale, Michael T ; Stupack, Dwayne G ; Schlaepfer, David D</creatorcontrib><description>FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.</description><identifier>ISSN: 2767-9764</identifier><identifier>EISSN: 2767-9764</identifier><identifier>DOI: 10.1158/2767-9764.CRC-24-0382</identifier><identifier>PMID: 39585085</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cell Line, Tumor ; Cell Nucleus - drug effects ; Cell Nucleus - metabolism ; Cell Survival - drug effects ; Cisplatin - pharmacology ; Female ; Focal Adhesion Kinase 1 - metabolism ; Focal Adhesion Protein-Tyrosine Kinases - antagonists &amp; inhibitors ; Focal Adhesion Protein-Tyrosine Kinases - metabolism ; Humans ; MAP Kinase Signaling System - drug effects ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology</subject><ispartof>Cancer research communications, 2024-12, Vol.4 (12), p.3165</ispartof><rights>2024 The Authors; Published by the American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0009-0003-3726-7243 ; 0000-0003-4814-9210 ; 0009-0008-2716-8280 ; 0000-0001-7998-9963 ; 0009-0008-2712-0922 ; 0000-0002-7422-4213 ; 0000-0003-4396-5745 ; 0009-0002-0136-6162 ; 0000-0003-1088-624X ; 0000-0001-8412-2889 ; 0000-0003-3181-6742 ; 0009-0005-9146-0233 ; 0000-0003-4755-1750 ; 0000-0003-0888-2004 ; 0009-0004-5641-8905</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39585085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yichi</creatorcontrib><creatorcontrib>Ojalill, Marjaana</creatorcontrib><creatorcontrib>Boyer, Antonia</creatorcontrib><creatorcontrib>Chen, Xiao Lei</creatorcontrib><creatorcontrib>Tahon, Elise</creatorcontrib><creatorcontrib>Thivolle Lioux, Gaëtan</creatorcontrib><creatorcontrib>Xia, Marvin</creatorcontrib><creatorcontrib>Abbas, Maryam</creatorcontrib><creatorcontrib>Soylu, Halime Meryem</creatorcontrib><creatorcontrib>Flieder, Douglas B</creatorcontrib><creatorcontrib>Connolly, Denise C</creatorcontrib><creatorcontrib>Molinolo, Alfredo A</creatorcontrib><creatorcontrib>McHale, Michael T</creatorcontrib><creatorcontrib>Stupack, Dwayne G</creatorcontrib><creatorcontrib>Schlaepfer, David D</creatorcontrib><title>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</title><title>Cancer research communications</title><addtitle>Cancer Res Commun</addtitle><description>FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cell Line, Tumor</subject><subject>Cell Nucleus - drug effects</subject><subject>Cell Nucleus - metabolism</subject><subject>Cell Survival - drug effects</subject><subject>Cisplatin - pharmacology</subject><subject>Female</subject><subject>Focal Adhesion Kinase 1 - metabolism</subject><subject>Focal Adhesion Protein-Tyrosine Kinases - antagonists &amp; inhibitors</subject><subject>Focal Adhesion Protein-Tyrosine Kinases - metabolism</subject><subject>Humans</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><issn>2767-9764</issn><issn>2767-9764</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkF1LwzAUhoMobsz9BCWX3nQmadKkl6M4FYcT3X04TRONdO1MWsF_b8t0eHVeDu8HPAhdUrKgVKgbJjOZ5DLji-KlSBhPSKrYCZoe_6f_9ATNY_wghDApucjSczRJc6EEUWKKtk-9qS0EvGoN1HhZvdvo2wY_-gaixc-h7azpIoY38E3scOHjvobON_i1CzZGPKjNFwQPDS4gGN-0O7hAZw7qaOe_d4a2q9ttcZ-sN3cPxXKdGEqYSDixxliXARiQhJUpZEK5SlhXQq6EgFxClrnScUHzylGZK2WVqgQzXHKVztD1oXYf2s_exk7vfDS2rqGxbR91SlOWUaoEHaziYDWhjTFYp_fB7yB8a0r0iFSPuPSISw9INeN6RDrkrn4n-nJnq2PqD2D6Aw3PckY</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Zhang, Yichi</creator><creator>Ojalill, Marjaana</creator><creator>Boyer, Antonia</creator><creator>Chen, Xiao Lei</creator><creator>Tahon, Elise</creator><creator>Thivolle Lioux, Gaëtan</creator><creator>Xia, Marvin</creator><creator>Abbas, Maryam</creator><creator>Soylu, Halime Meryem</creator><creator>Flieder, Douglas B</creator><creator>Connolly, Denise C</creator><creator>Molinolo, Alfredo A</creator><creator>McHale, Michael T</creator><creator>Stupack, Dwayne G</creator><creator>Schlaepfer, David D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0003-3726-7243</orcidid><orcidid>https://orcid.org/0000-0003-4814-9210</orcidid><orcidid>https://orcid.org/0009-0008-2716-8280</orcidid><orcidid>https://orcid.org/0000-0001-7998-9963</orcidid><orcidid>https://orcid.org/0009-0008-2712-0922</orcidid><orcidid>https://orcid.org/0000-0002-7422-4213</orcidid><orcidid>https://orcid.org/0000-0003-4396-5745</orcidid><orcidid>https://orcid.org/0009-0002-0136-6162</orcidid><orcidid>https://orcid.org/0000-0003-1088-624X</orcidid><orcidid>https://orcid.org/0000-0001-8412-2889</orcidid><orcidid>https://orcid.org/0000-0003-3181-6742</orcidid><orcidid>https://orcid.org/0009-0005-9146-0233</orcidid><orcidid>https://orcid.org/0000-0003-4755-1750</orcidid><orcidid>https://orcid.org/0000-0003-0888-2004</orcidid><orcidid>https://orcid.org/0009-0004-5641-8905</orcidid></search><sort><creationdate>20241201</creationdate><title>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</title><author>Zhang, Yichi ; Ojalill, Marjaana ; Boyer, Antonia ; Chen, Xiao Lei ; Tahon, Elise ; Thivolle Lioux, Gaëtan ; Xia, Marvin ; Abbas, Maryam ; Soylu, Halime Meryem ; Flieder, Douglas B ; Connolly, Denise C ; Molinolo, Alfredo A ; McHale, Michael T ; Stupack, Dwayne G ; Schlaepfer, David D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1025-40eccef6aaca702b3a658fd5efba9855a97a66fbf4519df17988e88d52c47483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cell Line, Tumor</topic><topic>Cell Nucleus - drug effects</topic><topic>Cell Nucleus - metabolism</topic><topic>Cell Survival - drug effects</topic><topic>Cisplatin - pharmacology</topic><topic>Female</topic><topic>Focal Adhesion Kinase 1 - metabolism</topic><topic>Focal Adhesion Protein-Tyrosine Kinases - antagonists &amp; inhibitors</topic><topic>Focal Adhesion Protein-Tyrosine Kinases - metabolism</topic><topic>Humans</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yichi</creatorcontrib><creatorcontrib>Ojalill, Marjaana</creatorcontrib><creatorcontrib>Boyer, Antonia</creatorcontrib><creatorcontrib>Chen, Xiao Lei</creatorcontrib><creatorcontrib>Tahon, Elise</creatorcontrib><creatorcontrib>Thivolle Lioux, Gaëtan</creatorcontrib><creatorcontrib>Xia, Marvin</creatorcontrib><creatorcontrib>Abbas, Maryam</creatorcontrib><creatorcontrib>Soylu, Halime Meryem</creatorcontrib><creatorcontrib>Flieder, Douglas B</creatorcontrib><creatorcontrib>Connolly, Denise C</creatorcontrib><creatorcontrib>Molinolo, Alfredo A</creatorcontrib><creatorcontrib>McHale, Michael T</creatorcontrib><creatorcontrib>Stupack, Dwayne G</creatorcontrib><creatorcontrib>Schlaepfer, David D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yichi</au><au>Ojalill, Marjaana</au><au>Boyer, Antonia</au><au>Chen, Xiao Lei</au><au>Tahon, Elise</au><au>Thivolle Lioux, Gaëtan</au><au>Xia, Marvin</au><au>Abbas, Maryam</au><au>Soylu, Halime Meryem</au><au>Flieder, Douglas B</au><au>Connolly, Denise C</au><au>Molinolo, Alfredo A</au><au>McHale, Michael T</au><au>Stupack, Dwayne G</au><au>Schlaepfer, David D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</atitle><jtitle>Cancer research communications</jtitle><addtitle>Cancer Res Commun</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>4</volume><issue>12</issue><spage>3165</spage><pages>3165-</pages><issn>2767-9764</issn><eissn>2767-9764</eissn><abstract>FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.</abstract><cop>United States</cop><pmid>39585085</pmid><doi>10.1158/2767-9764.CRC-24-0382</doi><orcidid>https://orcid.org/0009-0003-3726-7243</orcidid><orcidid>https://orcid.org/0000-0003-4814-9210</orcidid><orcidid>https://orcid.org/0009-0008-2716-8280</orcidid><orcidid>https://orcid.org/0000-0001-7998-9963</orcidid><orcidid>https://orcid.org/0009-0008-2712-0922</orcidid><orcidid>https://orcid.org/0000-0002-7422-4213</orcidid><orcidid>https://orcid.org/0000-0003-4396-5745</orcidid><orcidid>https://orcid.org/0009-0002-0136-6162</orcidid><orcidid>https://orcid.org/0000-0003-1088-624X</orcidid><orcidid>https://orcid.org/0000-0001-8412-2889</orcidid><orcidid>https://orcid.org/0000-0003-3181-6742</orcidid><orcidid>https://orcid.org/0009-0005-9146-0233</orcidid><orcidid>https://orcid.org/0000-0003-4755-1750</orcidid><orcidid>https://orcid.org/0000-0003-0888-2004</orcidid><orcidid>https://orcid.org/0009-0004-5641-8905</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2767-9764
ispartof Cancer research communications, 2024-12, Vol.4 (12), p.3165
issn 2767-9764
2767-9764
language eng
recordid cdi_proquest_miscellaneous_3132611851
source PubMed Central(OpenAccess)
subjects Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cell Line, Tumor
Cell Nucleus - drug effects
Cell Nucleus - metabolism
Cell Survival - drug effects
Cisplatin - pharmacology
Female
Focal Adhesion Kinase 1 - metabolism
Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors
Focal Adhesion Protein-Tyrosine Kinases - metabolism
Humans
MAP Kinase Signaling System - drug effects
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
title Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A21%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nuclear%20Focal%20Adhesion%20Kinase%20Protects%20against%20Cisplatin%20Stress%20in%20Ovarian%20Carcinoma&rft.jtitle=Cancer%20research%20communications&rft.au=Zhang,%20Yichi&rft.date=2024-12-01&rft.volume=4&rft.issue=12&rft.spage=3165&rft.pages=3165-&rft.issn=2767-9764&rft.eissn=2767-9764&rft_id=info:doi/10.1158/2767-9764.CRC-24-0382&rft_dat=%3Cproquest_cross%3E3132611851%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1025-40eccef6aaca702b3a658fd5efba9855a97a66fbf4519df17988e88d52c47483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3132611851&rft_id=info:pmid/39585085&rfr_iscdi=true